Form 4: Revolution Medicines CFO Exercises Options and Sells Shares Under 10b5-1 Plan

Chief Financial Officer of Revolution Medicines, Jack Anders, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On October 11, 2024, Jack Anders, the CFO of Revolution Medicines, exercised stock options to acquire 10,000 shares of common stock at a price of $2.68 per share.
• Simultaneously, Anders sold 10,000 shares of common stock at a weighted average price of $50.2979 per share, with individual sales prices ranging from $50.00 to $50.78.
• These transactions were executed under a 10b5-1 trading plan adopted by Anders on March 14, 2024.
• Following these transactions, Anders directly owns 98,932 shares of Revolution Medicines common stock, which includes 50,000 restricted stock units, and 2,814 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions under a pre-arranged plan. There's no indication of unusual activity or concern.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock transactions.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The use of a 10b5-1 trading plan is a common method for corporate insiders to sell shares without raising concerns about insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the transactions were pre-planned and not based on any inside information.

Key Dates